Investigators hope to learn which strategies work best to help Veterans who are not benefiting from their first PTSD treatment or not completing between-session homework assignments regularly that might improve treatment response. The investigators also want to learn how best to match the right type and amount of treatment to each individual Veteran.

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma.

The Diet study will determine the effectiveness of two diets utilizing FODMAP (Fermentable Oligo-, Di- and Mono-saccharides and Polyols) carbohydrates.

The Preventable study is investigating the role of statins in older adults, to determine the risk/benefit for prevention of cardiovascular disease or dementia at baseline, and to see if statins may reduce death, dementia, and persistent disability, mild cognitive impairment and dementia, and cardiovascular events.

The Reflection study enrolled Veterans who opted to be screened with Galleri, a multi-cancer early detection blood test which can detect the presence of 50+ cancers at time of blood draw.